Management of Kawasaki disease in resource-limited settings.
From the *Pediatric Allergy Immunology Unit, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India; †Department of Cardiology, Boston Children's Hospital, and Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; ‡Department of Pediatric Hematology, Immunology and Infectious Disease, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; §Murdoch Childrens Research Institute, Parkville; ¶Department of Paediatrics, University of Melbourne, Parkville; and ‖Department of Paediatric Infectious Diseases, Monash Children's Hospital, Clayton, Victoria, Australia.
Surjit
S
Singh
Jane W
JW
Newburger
Taco
T
Kuijpers
David
D
Burgner
D001241:Aspirin / Q000627:therapeutic use*; D003906:Developing Countries; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D009080:Mucocutaneous Lymph Node Syndrome / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*
D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D001241:Aspirin